secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001683168-24-003779
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences CEO Eisenberg and CSO Lockshin depart; CFO Parslow named interim CEO
--------------------------------------------------------------------------------

- Jeffrey F. Eisenberg stepped down as CEO and resigned as director effective May 16, 2024.
- Dr. Curtis Lockshin stepped down as Chief Scientific Officer, effective May 16, 2024.
- James F. Parslow, CFO since April 2017, appointed interim CEO; continues as principal financial officer.
- Parslow is a CPA with over 35 years experience; no related-party transactions or family relationships noted.
- Company advancing DNase oncology program toward Phase 1; preclinical data expected before year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/0001683168-24-003779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824003779/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-003779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer